Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2025)

Syndax Pharmaceuticals has reported Receivables over the past 3 years, most recently at $66.1 million for Q4 2025.

  • Quarterly results put Receivables at $66.1 million for Q4 2025, up 488.2% from a year ago — trailing twelve months through Dec 2025 was $66.1 million (up 488.2% YoY), and the annual figure for FY2025 was $66.1 million, up 642.48%.
  • Receivables for Q4 2025 was $66.1 million at Syndax Pharmaceuticals, up from $46.3 million in the prior quarter.
  • Over the last five years, Receivables for SNDX hit a ceiling of $66.1 million in Q4 2025 and a floor of $1.2 million in Q4 2023.
  • Median Receivables over the past 3 years was $31.0 million (2025), compared with a mean of $31.2 million.
  • Biggest five-year swings in Receivables: surged 815.81% in 2024 and later surged 488.2% in 2025.
  • Syndax Pharmaceuticals' Receivables stood at $1.2 million in 2023, then surged by 815.81% to $11.2 million in 2024, then surged by 488.2% to $66.1 million in 2025.
  • The last three reported values for Receivables were $66.1 million (Q4 2025), $46.3 million (Q3 2025), and $36.1 million (Q2 2025) per Business Quant data.